End-of-day quote
Taipei Exchange
23:00:00 30/05/2024 BST
|
5-day change
|
1st Jan Change
|
17.3
TWD
|
-0.86%
|
|
-3.35%
|
-16.43%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
1,087
|
943.2
|
862.8
|
1,045
|
Enterprise Value (EV)
1 |
810.8
|
718.8
|
676.6
|
1,455
|
P/E ratio
|
-75.5
x
|
-40.2
x
|
-20.2
x
|
-13
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.7
x
|
7.29
x
|
6.45
x
|
7.87
x
|
EV / Revenue
|
8
x
|
5.56
x
|
5.06
x
|
11
x
|
EV / EBITDA
|
-92.8
x
|
-49.1
x
|
-21.4
x
|
-33.7
x
|
EV / FCF
|
-44.1
x
|
-29.5
x
|
-34.6
x
|
-2.02
x
|
FCF Yield
|
-2.27%
|
-3.39%
|
-2.89%
|
-49.5%
|
Price to Book
|
2.65
x
|
2.47
x
|
2.54
x
|
2.35
x
|
Nbr of stocks (in thousands)
|
43,465
|
43,465
|
43,465
|
50,465
|
Reference price
2 |
25.00
|
21.70
|
19.85
|
20.70
|
Announcement Date
|
26/04/21
|
19/05/22
|
06/04/23
|
30/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
77.8
|
65.28
|
101.4
|
129.4
|
133.8
|
132.7
|
EBITDA
1 |
-7.559
|
-25.9
|
-8.735
|
-14.63
|
-31.67
|
-43.19
|
EBIT
1 |
-12.46
|
-30.65
|
-13.87
|
-22.74
|
-44.45
|
-59.18
|
Operating Margin
|
-16.01%
|
-46.95%
|
-13.69%
|
-17.58%
|
-33.22%
|
-44.6%
|
Earnings before Tax (EBT)
1 |
-12.57
|
-35.32
|
-9.495
|
-23.77
|
-42.7
|
-72.63
|
Net income
1 |
-13.39
|
-35.11
|
-11.21
|
-23.43
|
-42.72
|
-72.65
|
Net margin
|
-17.21%
|
-53.78%
|
-11.06%
|
-18.12%
|
-31.93%
|
-54.74%
|
EPS
2 |
-0.6100
|
-1.600
|
-0.3312
|
-0.5400
|
-0.9828
|
-1.597
|
Free Cash Flow
1 |
-10.36
|
-10.61
|
-18.38
|
-24.35
|
-19.55
|
-719.9
|
FCF margin
|
-13.32%
|
-16.26%
|
-18.13%
|
-18.83%
|
-14.61%
|
-542.48%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21/09/20
|
21/09/20
|
26/04/21
|
19/05/22
|
06/04/23
|
30/04/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
410
|
Net Cash position
1 |
127
|
79.6
|
276
|
224
|
186
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-9.499
x
|
Free Cash Flow
1 |
-10.4
|
-10.6
|
-18.4
|
-24.4
|
-19.6
|
-720
|
ROE (net income / shareholders' equity)
|
-7.76%
|
-23.7%
|
-4.15%
|
-5.92%
|
-11.8%
|
-18.5%
|
ROA (Net income/ Total Assets)
|
-4.23%
|
-10.8%
|
-2.79%
|
-3.27%
|
-6.92%
|
-5.17%
|
Assets
1 |
316.8
|
325.7
|
402.1
|
716.6
|
617.6
|
1,405
|
Book Value Per Share
2 |
7.550
|
5.950
|
9.420
|
8.790
|
7.820
|
8.800
|
Cash Flow per Share
2 |
2.220
|
2.060
|
4.900
|
2.400
|
1.770
|
1.360
|
Capex
1 |
11.9
|
0.64
|
8.85
|
12.7
|
10.5
|
665
|
Capex / Sales
|
15.3%
|
0.98%
|
8.73%
|
9.79%
|
7.85%
|
501.34%
|
Announcement Date
|
21/09/20
|
21/09/20
|
26/04/21
|
19/05/22
|
06/04/23
|
30/04/24
|
|
1st Jan change
|
Capi.
|
---|
| -16.43% | 26.84M | | -38.56% | 8.39B | | +0.18% | 3.32B | | +9.29% | 2.49B | | -18.21% | 2.06B | | -24.57% | 1.59B | | +32.37% | 1.15B | | -7.64% | 704M | | +8.42% | 678M | | -29.59% | 508M |
Bio Diagnostics & Testing
|